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Abstract Introduction: In spite of tremendous progress in the medical and surgical treatment of children with
congenital heart disease and dilated cardiomyopathy achieved during the past few decades, for some children a
heart transplant remains the only option. Clinically relevant benefits of intracoronary injection of autologous
stem cells on cardiac function and remodelling have been demonstrated in adult patients with acute
myocardial infarction. Experience with autologous stem cell therapy in children with severe congenital or
acquired pump failure is limited to a small number of case reports. Method and results: Between 2006 and
2010, nine severely ill children were treated with intracoronary infusion of autologous bone marrow-derived
mononuclear cells as part of a compassionate therapy in our centre. No procedure-related unexpected adverse
events occurred. There was one patient on extracorporeal membrane oxygenation who died of haemorrhage
unrelated to the procedure; three patients proceeded to heart transplantation once a donor heart became
available. The other five patients showed an improvement with respect to New York Heart Association
classification (greater than or equal to 1), brain natriuretic peptide serum levels, and ejection fraction.
Conclusion: Similar to adults, intracoronary injection of autologous bone marrow cell is technically feasible and
safe for children. On the basis of our data, we propose to perform a pilot study for children with congestive
heart failure, to formally assess the efficacy of intracoronary autologous bone marrow cell therapy.
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A
MONG THE MORE SEVERE CONGENITAL ABNORMAL-
ities, cardiac malformations play an important
qualitative and quantitative role. The estimated
incidence of 10 per 1000 live births seems to be a
conservative estimate for the prevalence of cardiac
malformations.1 Owing to tremendous advances in the
medical and surgical care of children with congenital
heart disease over the past few decades, survival into
adulthood has become a reality; however, some
patients with complex malformations, despite best
surgical and medical efforts, ultimately require a heart
transplant.
Dilated cardiomyopathy is also associated with
considerable morbidity and mortality. About one-third
of children diagnosed with dilated cardiomyopathy die
within the first year after diagnosis, unless they receive a
heart transplant.2–4
The Pediatric Heart Centre in Giessen offers the
full therapeutic spectrum for heart failure in children,
ranging from basic anticongestive treatment to
implantation of assist devices and heart transplantation.
Because of side effects of the immunosuppressive
agents and the decreasing function of the trans-
planted organ over time, the long-term outcome
Correspondence to: Professor Dr D. Schranz, MD, Pediatric Heart Center,
Justus-Liebig University, Feulgenstrasse 12, 35385 Giessen, Germany. Tel: 049
641 9943461; Fax: 049 641 9943469; E-mail: Dietmar.Schranz@paediat.med.
uni-giessen.de
*Institute for Transfusion Medicine, German Red Cross Blood Donor Service
East, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
after heart transplantation remains limited. The
modest long-term outcome and the paucity of donor
organs5 fuel the ongoing search for improved
medical and surgical therapy, and for therapeutic
alternatives in patients with congenital heart disease
and dilated cardiomyopathy.
Over the last decade, it has become apparent that
the heart possesses modest regenerative capacity
with respect to cardiomyocytes and new blood vessel
formation.6 Human bone marrow-derived proangioge-
netic cells were shown to improve angiogenesis and
neovascularisation.7 Moreover, a sizeable fraction of
cardiomyocytes refreshes the heart after injury or under
conditions of pressure overload.8,9 However, in chronic
pathological conditions of cardiac de-compensation,
the endogenous repair capacity may not be sufficient.
Recently, it was shown that in healthy individuals
cardiomyocyte renewal decreases from 2% turnover
annually at the age of 10 years to 1% at the age of
27 years and 0.45% at the age of 75 years.10
Extrapolation of this scale to children younger than
10 years suggests an even higher amount of cardio-
myocyte renewal in healthy infants. Children with
anomalous left coronary arteries arising from the
pulmonary artery, who present with severely reduced
ventricular function, generally recover after surgery and
acquire normal ventricular function over time.11
Initial pilot studies with intracoronary infusion
of autologous bone marrow-derived cells in adults
with acute myocardial infarction reported an
improvement in global left ventricular ejection
fraction, reduced end-systolic left ventricular volumes,
and improved perfusion in the infarcted area.12–15
These beneficial effects were confirmed in the thus
far largest double-blind, randomised multi-centre
REPAIR-AMI trial.16 However, these data are not
uncontested, as another large study did not show any
benefit on left ventricular functional parameters.17
Subtle differences in cell processing, affecting cell
functionality, were proposed as an explanation for the
divergent outcomes. Meta-analyses confirmed clini-
cally relevant benefits of intracoronary bone marrow
cell therapy on cardiac function and remodelling in
adult patients.18,19
We hypothesise that particularly in young or
even very young patients considerable regenerative
potential of the heart is preserved and that cardiac
cell therapy might be of even greater value than in
adults.
Methods
Between 2006 and 2010, we performed intracor-
onary infusion of autologous bone marrow-derived
mononuclear cells in nine patients at our heart
transplantation centre. In each of the described
cases, congestive heart failure developed despite
maximum surgical and medical care. At the time of
cell therapy, three patients were on assist devices.
Positive inotropic substances were used in four
patients and a careful switch to anticongestive treat-
ment was performed in two patients. Anticongestive
treatment consisted of beta-1-selective beta-blockers,
angiotensin converting enzyme-inhibitors, and spir-
onolactone. Anticongestive treatment proved not to be
sufficient, because both patients additionally required
diuretics. In all, five patients were listed for heart
transplantation; in one case, heart transplantation was
not an option because the patient was from a non-
European Union country.
In all cases, intracoronary bone marrow cell
administration was considered as compassionate
treatment to stabilise the patients’ clinical condi-
tion. Ejection fraction, brain natriuretic peptide
serum levels, and New York Heart Association
classification were regularly assessed during follow-
up according to the clinical conditions of the
patient. The local ethics committee approved the
procedure as a compassionate approach, and written
informed consent was obtained from the parents.
In each case, a bone marrow aspirate of 1–2
millilitres per kilogram – maximum of 60 milli-
litres – was drawn under systemic sedation and
analgesia, as well as local anaesthesia. Bone marrow
and autologous serum was processed according to
Good Manufacturing Practice standards13 by the
Institute for Transfusion Medicine and Immunohe-
matology of the Goethe University Clinic, Frank-
furt. Cells were suspended in a 4–12-millilitre
solution and re-infused on the same day using the
stop-flow technique as described before.13
Over-the-wire coronary balloon catheters of
widths between 1.5 and 2.5 millimetres and lengths
of 8 to 20 millimetres were advanced into the
selected coronary arteries without the use of an
additional guiding catheter. Coronary arteries were
selected on the basis of regions of pronounced
dysfunction of the supplied ventricular area (Fig 1a).
Infused volumes and selected arteries are shown in
Table 2. To allow for adhesion and potential trans-
migration of the infused cells through the endothe-
lium, the balloon was inflated with low pressure (less
than 1–2 atmospheres) to completely block blood flow
for 3 minutes, while the cell suspension was infused
distally to the occluding balloon through the central
port of the balloon catheter, after the guide wire was
removed (Fig 1b). After completion of intracoronary
cell administration, coronary angiography was re-
peated to ascertain vessel patency and unimpeded flow
of contrast material.
Statistical assessment of the possible benefits of
cardiac cell therapy is beyond the scope of this
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manuscript. Owing to the fact that all patients were
severely ill, cell therapy was only part of the
strategy and heart transplantation remained the
therapeutic goal, provided that a suitable donor
organ would become available before a significant
improvement in clinical condition was seen (New York
Heart Association improvement greater than or
equal to 1 for at least 3 months).
Results
In all, nine patients received intracoronary infusion
of bone marrow cells as described. During applica-
tion using the stop-flow technique, moderate
ST-segment changes were documented; however,
no increase in cardiac troponin T was observed after
the procedure, providing evidence that intracoron-
ary application of autologous bone marrow-derived
cells is feasible and safe. The specification of the
infused cells is given in Table 1. No acute adverse
events were observed; all treated vessels were and
remained patent and unaffected. The characteri-
stics of the patients are summarised in Table 2. After
donor organs became available, two patients proceeded
to heart transplantation – 48 days and 32 days,
respectively, after cell therapy, patient I and patient II –
that is, before the efficacy of cell therapy could be
ascertained.
The first patient suffered from a dilated cardio-
myopathy likely because of an anthracyclin that she
had received for treatment of nephroblastoma at the
age of 5 years. She had been on a left ventricular
assist device at the time of cell therapy and
proceeded to heart transplantation after 48 days.
The second patient with idiopathic dilated
cardiomyopathy was treated with a maze operation
for the right atrium and a Carpentier–Edwards Ring
at the tricuspid valve 2 months before the cell
therapy. Further deterioration of the clinical condi-
tion led to listing for heart transplantation and a
cell therapy was performed. A donor heart became
available 32 days after cell therapy, and the patient
received a heart transplant before the efficacy of cell
therapy could be ascertained.
The third patient with idiopathic dilated cardi-
omyopathy who had been on an assist device showed
a clinical benefit after cell therapy, which cannot be
clearly discriminated from beneficial effects from
the assist device that was implanted 4 weeks before
cell therapy. The improvement of his clinical condition
allowed removal of the assist device. However, another
clinical deterioration followed and a secondary assist
device was implanted 7 months after explantation of
the first device. The patient was finally transplanted
when an organ became available.
The fourth patient suffered from double outlet
right ventricle, that is, Taussig–Bing Complex.
This patient was postnatally treated with a ductal
stent and a pulmonary artery banding. After
surgical repair at the age of 5 months – arterial
Figure 1.
Infusion of bone marrow cells (BMC).
Table 1. Characteristics of infused cells.
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switch operation with occlusion of the ventricular
septal defect and aortic arch repair – the patient
showed a severely reduced cardiac and pulmonary
function and was treated with extracorporeal mem-
brane oxygenation. An autologous bone marrow cell
therapy was performed, yet the patient died 5 weeks
later while on extracorporeal membrane oxygenation
with severely reduced cardiac and pulmonary function.
She succumbed to a haemorrhagic infarction of the
middle cerebral artery and pulmonary haemorrhage.
The fifth patient with pulmonary atresia and
ventricular septal defect suffered from left ventri-
cular dysfunction due to coronary ischaemia –
thrombus formation in the left anterior coronary
descending from the right coronary artery – after
surgical repair – including unifocalisation of main
pulmonary collateral arteries, homograft implanta-
tion at the side of pulmonary atresia, and closure of
the atrial septal defect and ventricular septal defect.
The sixth patient was already reported in 2008 as
a case report.20 He suffered from dilative cardio-
myopathy caused by a non-acute myocarditis.
The seventh patient suffered from severe dilated
left ventricular cardiomyopathy from birth, prob-
ably due to ischaemia presumed secondary to opioid
abuse of the mother during pregnancy.
The eighth patient suffered from dilative cardi-
omyopathy with severe mitral insufficiency caused
by perinatal Coxsackie B Virus myocarditis and
an infarction in the region of the left circumflex
coronary artery. Late enhancement was documented
in the infarcted area with magnetic resonance
imaging, and autologous bone marrow cell therapy
was performed several weeks after the ischaemic
event. After 3 weeks, the mitral valve was recon-
structed with a bioabsorbable Kalangos ring and
fixation of the posterior leaflet. After 1 week of the
operation, the patient developed ventricular and
supraventricular tachycardia requiring amiodarone
treatment. The clinical condition of the patient
significantly improved in the following months, no
arrythmia was documented in the follow-up, and
amiodarone was discontinued 5 months later.
The ninth patient – age 11 months – had a hypo-
plastic left heart syndrome after hybrid comprehensive
stage two, already reported before.21 In response to the
cell therapy, his condition improved significantly.
Meanwhile, total cava-pulmonary connection as stage
III is completed.
Discussion
Here we report that autologous cardiac cell admini-
stration is technically feasible and safe in children.
Overall, no procedure-related unexpected adverse
events occurred in the present series.Ta
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The severity of the initial clinical status of the
patients limits a statistical assessment of the
possible benefits of intracoronary administration of
bone marrow-derived cells. However, in the absence
of good evidence for the value of intracoronary bone
marrow cell administration in paediatric heart
disease, denial of an available transplant would
have been unethical. Therefore, according to our
protocol, patients received heart transplants after
cell therapy, as a donor organ became available.
However, one patient died soon after cell therapy of
infarction of the middle cerebral artery and lung
haemorrhage while being on extracorporeal mem-
brane oxygenation. Both events were not temporally
related to the cell therapy, and thus likely causally
unrelated.
There were three patients with dilated cardio-
myopathy who showed a definitive improvement in
their clinical condition, brain natriuretic peptide
serum levels, and ejection fraction during short-
term (2–3 months) and long-term (24–52 months)
follow-up. There were two further patients with
congenital heart disease who also apparently
benefited from autologous intracoronary bone
marrow-derived cell application. The temporal
association of cell therapy and clinical improvement
suggests a causal relationship, although this
observation cannot formally be ascertained.
The beneficial effect of intracoronary administra-
tion of bone marrow-derived cells on neovascular-
isation is conclusively documented.7 However, the
process of cardiomyocyte renewal, which remains
controversially discussed in adult mammals, might
play a much more prominent role in children, as
cardiomyocyte turnover in children is higher than
in adults.10 In addition, direct clinical evidence for
an enhanced regenerative capacity of the paediatric
myocardium11 has been provided. In comparison
with adults and patients with risk factors for
cardiovascular diseases, the children’s bone marrow
showed considerably higher content of cells expres-
sing the stem cell markers CD34 and CD133,
which may reflect a superior regenerative capacity of
juvenile bone marrow.
These encouraging data may indeed serve as a
rationale to perform a pilot study in children with
refractory congestive heart failure, in order to assess
possible beneficial effects of autologous intracor-
onary bone marrow cell therapy. However, it should
be noticed that dilated cardiomyopathy subsumes
patients with one or two dilated ventricles with a
variety of underlying (heart) diseases. In addition,
patients with genetic defects may present with the
diagnosis of dilated cardiomyopathy. Especially in
these patients, autologous cell therapy might not be
beneficial, because genetic defects in cardiomyogenesis
might be responsible for the clinical syndrome; that is,
in these patients, cardiac regeneration might be
genetically limited. Owing to the variety of under-
lying nosologic entities, a controlled study with
patients suffering from any dilated cardiomyopathy
might not be performed in first line. Instead, we are
planning a pilot study for infants and children with
single ventricular hearts, Norwood stage II and III,
reduced heart function, and severely impaired clinical
status – New York Heart Association III), in order to
ascertain a potential beneficial effect of intracoronary
infusion of autologous bone marrow-derived mono-
nuclear cells in a rather homogeneous group of patients
with presumed cardiac regenerative capacity.
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